Next Generation Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 – 2032
The Global Next Generation Cancer Diagnostics Market reached USD 15.5 billion in 2023 and is projected to grow at a 10% CAGR from 2024 to 2032. The surge in demand is primarily fueled by the shift towards personalized medicine, which tailors treatments based on individual genetic and molecular data. Advanced diagnostic technologies, including next-generation sequencing (NGS) and liquid biopsy, are central to identifying genetic mutations and specific cancer biomarkers. These capabilities enhance early detection and optimize targeted therapy selection.
Next-generation cancer diagnostics introduce advanced tools and techniques enabling precise, early detection and personalized cancer analysis. These advancements improve disease monitoring and risk assessment, allowing for the refined selection of targeted therapies. By focusing on the unique genetic, molecular, and cellular characteristics of tumors, this market is leading a revolution in cancer care, driven by precision medicine's potential to achieve better clinical outcomes and more effective treatment.
The market is divided into products and services, with the products segment taking a significant share and expected to grow at a 9.8% CAGR over the forecast period. This segment includes instruments and kits & consumables, all essential for diagnostic accuracy and efficiency. Demand is high for advanced sequencing platforms, PCR machines, and imaging devices used widely across hospitals, laboratories, and research institutions, contributing significantly to market revenue.
Technologically, the next generation cancer diagnostics market from the NGS segment held 32.5% share in 2023 due to its ability to provide detailed genomic insights quickly and accurately. NGS's role in identifying genetic mutations and biomarkers is vital for early cancer detection and personalized treatment, with growing cancer prevalence, NGS innovations, and decreasing costs driving adoption.
In the U.S., the next-generation cancer diagnostics market is set to grow at a 9.5% CAGR through 2032. The country leads the market due to its advanced healthcare infrastructure, substantial R&D investments, and emphasis on innovation. The presence of prominent biotechnology and pharmaceutical firms, strong government backing for cancer research, and increased public awareness of early detection reinforces the U.S.'s position in this rapidly evolving field.
Next-generation cancer diagnostics introduce advanced tools and techniques enabling precise, early detection and personalized cancer analysis. These advancements improve disease monitoring and risk assessment, allowing for the refined selection of targeted therapies. By focusing on the unique genetic, molecular, and cellular characteristics of tumors, this market is leading a revolution in cancer care, driven by precision medicine's potential to achieve better clinical outcomes and more effective treatment.
The market is divided into products and services, with the products segment taking a significant share and expected to grow at a 9.8% CAGR over the forecast period. This segment includes instruments and kits & consumables, all essential for diagnostic accuracy and efficiency. Demand is high for advanced sequencing platforms, PCR machines, and imaging devices used widely across hospitals, laboratories, and research institutions, contributing significantly to market revenue.
Technologically, the next generation cancer diagnostics market from the NGS segment held 32.5% share in 2023 due to its ability to provide detailed genomic insights quickly and accurately. NGS's role in identifying genetic mutations and biomarkers is vital for early cancer detection and personalized treatment, with growing cancer prevalence, NGS innovations, and decreasing costs driving adoption.
In the U.S., the next-generation cancer diagnostics market is set to grow at a 9.5% CAGR through 2032. The country leads the market due to its advanced healthcare infrastructure, substantial R&D investments, and emphasis on innovation. The presence of prominent biotechnology and pharmaceutical firms, strong government backing for cancer research, and increased public awareness of early detection reinforces the U.S.'s position in this rapidly evolving field.
Report Content
CHAPTER 1 METHODOLOGY & SCOPE
1.1 Market scope & definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cancer
3.2.1.2 Growing advancement in diagnostic technologies
3.2.1.3 Increased investments in cancer research
3.2.1.4 Growing awareness and screening programs
3.2.2 Industry pitfalls & challenges
3.2.2.1 High costs of advanced diagnostics technologies
3.2.2.2 Stringent regulations and lengthy approval processes
3.3 Growth potential analysis
3.4 Future market trends
3.5 Technology landscape
3.6 Pricing analysis
3.7 Regulatory landscape
3.8 Porter’s analysis
3.9 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PRODUCT & SERVICE, 2021 – 2032 ($ MN)
5.1 Key trends
5.2 Products
5.2.1 Instruments
5.2.2 Kits & consumables
5.3 Services
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY TECHNOLOGY, 2021 – 2032 ($ MN)
6.1 Key trends
6.2 Next-generation sequencing (NGS)
6.3 Polymerase chain reaction (PCR)
6.4 DNA microarrays
6.5 Multiplexing
6.6 Other technologies
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY CANCER TYPE, 2021 – 2032 ($ MN)
7.1 Key trends
7.2 Breast cancer
7.3 Lung cancer
7.4 Colorectal cancer
7.5 Prostate cancer
7.6 Cervical cancer
7.7 Liver cancer
7.8 Other cancer types
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2032 ($ MN)
8.1 Key trends
8.2 Screening and early detection
8.3 Prognostics and monitoring
8.4 Therapy selection
8.5 Recurrence monitoring
8.6 Other applications
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2032 ($ MN)
9.1 Key trends
9.2 Hospitals & clinics
9.3 Diagnostic laboratories
9.4 Academic & research institutions
9.5 Other end users
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 ($ MN)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Agilent
11.2 Almac
11.3 Bio-Rad Laboratories
11.4 Exact Sciences
11.5 F. Hoffmann-La Roche
11.6 GenScript
11.7 Guardant Health
11.8 Illumina
11.9 Karkinos Healthcare
11.10 Qiagen
11.11 Koninklijke Philips
11.12 Thermo Fisher Scientific
CHAPTER 1 METHODOLOGY & SCOPE
1.1 Market scope & definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cancer
3.2.1.2 Growing advancement in diagnostic technologies
3.2.1.3 Increased investments in cancer research
3.2.1.4 Growing awareness and screening programs
3.2.2 Industry pitfalls & challenges
3.2.2.1 High costs of advanced diagnostics technologies
3.2.2.2 Stringent regulations and lengthy approval processes
3.3 Growth potential analysis
3.4 Future market trends
3.5 Technology landscape
3.6 Pricing analysis
3.7 Regulatory landscape
3.8 Porter’s analysis
3.9 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PRODUCT & SERVICE, 2021 – 2032 ($ MN)
5.1 Key trends
5.2 Products
5.2.1 Instruments
5.2.2 Kits & consumables
5.3 Services
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY TECHNOLOGY, 2021 – 2032 ($ MN)
6.1 Key trends
6.2 Next-generation sequencing (NGS)
6.3 Polymerase chain reaction (PCR)
6.4 DNA microarrays
6.5 Multiplexing
6.6 Other technologies
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY CANCER TYPE, 2021 – 2032 ($ MN)
7.1 Key trends
7.2 Breast cancer
7.3 Lung cancer
7.4 Colorectal cancer
7.5 Prostate cancer
7.6 Cervical cancer
7.7 Liver cancer
7.8 Other cancer types
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2032 ($ MN)
8.1 Key trends
8.2 Screening and early detection
8.3 Prognostics and monitoring
8.4 Therapy selection
8.5 Recurrence monitoring
8.6 Other applications
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2032 ($ MN)
9.1 Key trends
9.2 Hospitals & clinics
9.3 Diagnostic laboratories
9.4 Academic & research institutions
9.5 Other end users
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 ($ MN)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Agilent
11.2 Almac
11.3 Bio-Rad Laboratories
11.4 Exact Sciences
11.5 F. Hoffmann-La Roche
11.6 GenScript
11.7 Guardant Health
11.8 Illumina
11.9 Karkinos Healthcare
11.10 Qiagen
11.11 Koninklijke Philips
11.12 Thermo Fisher Scientific
